Dopaminergic influences on the P300 abnormality in Parkinson's disease.
This study was designed to evaluate the contribution of central dopaminergic mechanisms to the P300 event-related potential (P300) abnormality in Parkinson's disease. We measured the P300 in 37 non-demented patients with Parkinson's disease (19 de novo and 18 levodopa-treated) and 15 age-matched healthy volunteers. The P300 measurement was repeated in 14 de novo patients, after 6-12 months levodopa therapy. The severity of parkinsonian symptom was assessed using the UPDRS-motor scale. De novo patients showed prolonged P300 latency compared with levodopa-treated patients, as well as healthy volunteers. The levodopa therapy for 6-12 months significantly shortened the P300 latency and reduced the UPDRS-motor examination score in de novo patients. However, the percent changes in the P300 latency were not correlated with those in the UPDRS-motor examination score. These results indicate that the central dopaminergic mechanisms apart from those responsible for motor symptoms, may contribute to the P300 abnormality in Parkinson's disease.
Department of Neurology and the Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Y H
YH
Sohn
G W
GW
Kim
K
K
Huh
J S
JS
Kim
D000161:Acoustic Stimulation; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects*; D018913:Event-Related Potentials, P300; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008606:Mental Processes; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D011930:Reaction Time / Q000187:drug effects; D012720:Severity of Illness Index
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists; D007980:Levodopa; D004298:Dopamine